Editorial comment

摘要

A decade ago, The Institute of Medicine Report on Testosterone and Aging1 indicated that "the potential for testosterone therapy to increase risk for symptomatic prostatic hypertrophy is of major concern... but quantifying these risks will require randomized trials that include large number of men followed for multiple years." In relation to the development of prostate cancer, the report drew attention to the need for a study including a population of 5000 men followed for 3 to 5 years. The logistic and financial implications of such undertakings are enormous and little progress has occurred since. Most of the information on the effect of testosterone on prostate enlargement is drawn from trials assessing new delivery forms of testosterone, involve a limited number of participants, and typically have insufficient follow-up.